Fox Chase Cancer Center News

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become resistant to therapy. New research co-headed by a Fox Chase Cancer Center scientist helps explain why — and offers three strategies for making treatment more effective.

Jeffrey Farma, MD, FACS, Chair and Professor in the Department of Surgery, was honored today for his appointment to the Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology at Fox Chase Cancer Center.

Fox Chase Cancer Center clinical research nurse Colbi Carr, BSN, RN, recently became a member of the ECOG-ACRIN Research Group’s Oncology Nursing Committee.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this mutation could be targeted therapeutically.

A pilot program developed to educate healthcare providers about patient chemosensory dysfunction significantly improved providers’ knowledge and confidence in providing support to patients, according to a recent publication on the program from clinicians and researchers at Fox Chase Cancer Center.

A new paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid cystic carcinoma (ACC) after a molecular panel identified the presence of an atypical fusion gene.

Physicians at Fox Chase Cancer Center have now performed 10,000 surgeries using the da Vinci robotic surgical system, which has been essential in expanding access to the latest treatment options for cancer patients across multiple cancer specialties.

Andrea Califano, Dr, a leader in the field of systems biology, was recognized today at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction.